デフォルト表紙
市場調査レポート
商品コード
1417199

コレラワクチン市場レポート:2030年までの動向、予測、競合分析

Cholera Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日: | 発行: Lucintel | ページ情報: 英文 150 - page report | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

コレラワクチン市場レポート:2030年までの動向、予測、競合分析
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

コレラワクチンの動向と予測

世界のコレラワクチン市場は、2024年から2030年までのCAGR 9.0%で、2030年までに推定1,553億8,000万米ドルに達すると予想されています。この市場の主な原動力は、コレラ予防に対する認識と取り組みの高まり、政府主導の取り組みと世界の協力の促進が、集団的な行動と共通の目標に向けたことです。世界のコレラワクチン市場の将来は、病院や診療所、調査機関や学術研究所の市場での機会が有望に見えます。

コレラワクチン市場に関する洞察

Lucintelは、組換えbサブユニットを含む全細胞対コレラ菌O1が予測期間中に最も高い成長を遂げると予測しています。

この市場では、病院と診療所が引き続き最大のセグメントとなるでしょう。

北米は、予測期間中に最高の成長を遂げると予想されます。

よくある質問

Q.1コレラワクチンの市場規模はどれくらいですか:

A1.世界のコレラワクチン市場は、2030年までに推定1,553億8,000万米ドルに達すると予想されています。

Q.2コレラワクチン市場の成長予測は何ですか:

A2.世界のコレラワクチン市場は、2024年から2030年までCAGR 9.0%で成長すると予想されています。

Q.3コレラワクチン市場の成長に影響を与える主な要因は何ですか:

A3.この市場の主な原動力は、コレラ予防に対する意識の高まりと取り組みであり、政府主導の取り組みと世界の協力により、共同の行動と共通の目標に向けた進歩が促進されています。

Q4.市場の主要セグメントは:

A4.コレラワクチン市場の将来は、病院や診療所、調査機関や学術研究所の市場での機会があり、有望に見えます。

Q5.市場の主要企業は:

A5.主要なコレラワクチン会社は以下のとおりです。

  • Astellas Pharma
  • Celldex Therapeutics
  • Emergent BioSolutions
  • Eubiologics
  • Johnson &Johnson
  • Merck
  • Pfizer
  • PharmaChoice Canada
  • Sanofi
  • Takeda Pharmaceutical Company Limited

Q6.今後、最大となる市場セグメントは:

A6.Lucintelは、組換えbサブユニットを含む全細胞対コレラ菌O1が予測期間中に最も高い成長を遂げると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は:

A7.北米は、予測期間中に最高の成長を遂げると予想されます。

Q8.レポートのカスタマイズは可能か:

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のコレラワクチン市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向(2018~2023年)と予測(2024~2030年)
  • 世界のコレラワクチン市場動向(2018~2023年)と予測(2024~2030年)
  • ワクチンの種類別の世界のコレラワクチン市場
    • 組換えbサブユニットを含む全細胞対コレラ菌O1
    • オーラルO1とO139を殺害
  • 製品別の世界のコレラワクチン市場
    • デュコラル
    • シャンチョル
    • ヴァクチョーラ
    • ユービコールとユービコールプラス
    • その他
  • 最終用途産業別の世界のコレラワクチン市場
    • 病院と診療所
    • 調査と学術研究所
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のコレラワクチン市場
  • 北米のコレラワクチン市場
  • 欧州のコレラワクチン市場
  • アジア太平洋のコレラワクチン市場
  • その他地域のコレラワクチン市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • ワクチンの種類別の世界のコレラワクチン市場の成長機会
    • 製品別の世界のコレラワクチン市場の成長機会
    • 最終用途産業別の世界のコレラワクチン市場の成長機会
    • 地域別の世界のコレラワクチン市場の成長機会
  • 世界のコレラワクチン市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のコレラワクチン市場の生産能力拡大
    • 世界のコレラワクチン市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Astellas Pharma
  • Celldex Therapeutics
  • Emergent BioSolutions
  • Eubiologics
  • Johnson & Johnson
  • Merck
  • Pfizer
  • PharmaChoice Canada
  • Sanofi
  • Takeda Pharmaceutical Company Limited
目次

Cholera Vaccine Trends and Forecast

The future of the global cholera vaccine market looks promising with opportunities in the hospitals and clinics and research and academic laboratories markets. The global cholera vaccine market is expected to reach an estimated $155.38 billion by 2030 with a CAGR of 9.0% from 2024 to 2030. The major drivers for this market are growing awareness and efforts towards cholera prevention and government-driven initiatives and global collaborations are fostering collective action and progress towards common goals.

A more than 150-page report is developed to help in your business decisions.

Cholera Vaccine by Segment

The study includes a forecast for the global cholera vaccine by vaccine type, product, end use industry, and region.

Cholera Vaccine Market by Vaccine Type [Shipment Analysis by Value from 2018 to 2030]:

  • Whole Cell V. Cholerae O1 with Recombinant B-Subunit
  • Killed Oral O1 and O139

Cholera Vaccine Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Dukoral
  • Shanchol
  • Vaxchora
  • Euvichol and Euvichol-Plus

Cholera Vaccine Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Research and Academic Laboratories
  • Others

Cholera Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cholera Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cholera vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cholera vaccine companies profiled in this report include-

  • Astellas Pharma
  • Celldex Therapeutics
  • Emergent Biosolutions
  • Eubiologics
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Pharmachoice Canada
  • Sanofi
  • Takeda Pharmaceutical Company Limited

Cholera Vaccine Market Insights

Lucintel forecasts that whole cell v. cholerae O1 with recombinant b-subunit is expected to witness highest growth over the forecast period.

Within this market, hospitals and clinics will remain the largest segment.

North America is expected to witness highest growth over the forecast period.

Features of the Global Cholera Vaccine Market

Market Size Estimates: Cholera vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cholera vaccine market size by vaccine type, product, end use industry, and region in terms of value ($B).

Regional Analysis: Cholera vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine type, product, end use industry, and regions for the cholera vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cholera vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the cholera vaccine market size?

Answer: The global cholera vaccine market is expected to reach an estimated $155.38 billion by 2030.

Q.2 What is the growth forecast for cholera vaccine market?

Answer: The global cholera vaccine market is expected to grow with a CAGR of 9.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cholera vaccine market?

Answer: The major drivers for this market are growing awareness and efforts towards cholera prevention and government-driven initiatives and global collaborations are fostering collective action and progress towards common goals.

Q4. What are the major segments for cholera vaccine market?

Answer: The future of the cholera vaccine market looks promising with opportunities in the hospitals and clinics and research and academic laboratories markets.

Q5. Who are the key cholera vaccine market companies?

Answer: Some of the key cholera vaccine companies are as follows.

  • Astellas Pharma
  • Celldex Therapeutics
  • Emergent BioSolutions
  • Eubiologics
  • Johnson & Johnson
  • Merck
  • Pfizer
  • PharmaChoice Canada
  • Sanofi
  • Takeda Pharmaceutical Company Limited

Q6. Which cholera vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that whole cell v. cholerae O1 with recombinant b-subunit is expected to witness highest growth over the forecast period.

Q7. In cholera vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cholera vaccine market by vaccine type (whole cell V. cholerae O1 with recombinant B-subunit and killed oral O1 and O139), product (dukoral, shanchol, vaxchora, euvichol and euvichol-plus, and others), end use industry (hospitals and clinics, research and academic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cholera Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cholera Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cholera Vaccine Market by Vaccine Type
    • 3.3.1: Whole Cell V. Cholerae O1 with Recombinant B-Subunit
    • 3.3.2: Killed Oral O1 and O139
  • 3.4: Global Cholera Vaccine Market by Product
    • 3.4.1: Dukoral
    • 3.4.2: Shanchol
    • 3.4.3: Vaxchora
    • 3.4.4: Euvichol and Euvichol-Plus
    • 3.4.5: Others
  • 3.5: Global Cholera Vaccine Market by End Use Industry
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Research and Academic Laboratories
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cholera Vaccine Market by Region
  • 4.2: North American Cholera Vaccine Market
    • 4.2.2: North American Cholera Vaccine Market by End Use Industry: Hospitals and Clinics, Research and Academic Laboratories, and Others
  • 4.3: European Cholera Vaccine Market
    • 4.3.1: European Cholera Vaccine Market by Vaccine Type: Whole Cell V. Cholerae O1 with Recombinant B-Subunit and Killed Oral O1 and O139
    • 4.3.2: European Cholera Vaccine Market by End Use Industry: Hospitals and Clinics, Research and Academic Laboratories, and Others
  • 4.4: APAC Cholera Vaccine Market
    • 4.4.1: APAC Cholera Vaccine Market by Vaccine Type: Whole Cell V. Cholerae O1 with Recombinant B-Subunit and Killed Oral O1 and O139
    • 4.4.2: APAC Cholera Vaccine Market by End Use Industry: Hospitals and Clinics, Research and Academic Laboratories, and Others
  • 4.5: ROW Cholera Vaccine Market
    • 4.5.1: ROW Cholera Vaccine Market by Vaccine Type: Whole Cell V. Cholerae O1 with Recombinant B-Subunit and Killed Oral O1 and O139
    • 4.5.2: ROW Cholera Vaccine Market by End Use Industry: Hospitals and Clinics, Research and Academic Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cholera Vaccine Market by Vaccine Type
    • 6.1.2: Growth Opportunities for the Global Cholera Vaccine Market by Product
    • 6.1.3: Growth Opportunities for the Global Cholera Vaccine Market by End Use Industry
    • 6.1.4: Growth Opportunities for the Global Cholera Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Cholera Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cholera Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cholera Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Astellas Pharma
  • 7.2: Celldex Therapeutics
  • 7.3: Emergent BioSolutions
  • 7.4: Eubiologics
  • 7.5: Johnson & Johnson
  • 7.6: Merck
  • 7.7: Pfizer
  • 7.8: PharmaChoice Canada
  • 7.9: Sanofi
  • 7.10: Takeda Pharmaceutical Company Limited